In the Netherlands, participation in the National Immunisation Programme (NIP) is high, resulting in low incidences of most diseases included in the NIP. Yet coverage for vaccination against human papillomavirus (HPV) in girls is lower. Only a few severe adverse events following immunisation occurred. Reported adverse events are mostly mild and transient. Continuous monitoring of effectiveness and safety is necessary for the programme to remain optimal.
Changes in the vaccination schedule in 2014-2015 Since 2014, girls have been receiving a reduced number of doses against human papillomavirus (HPV). Two doses of HPV vaccine are offered to 12-year-old girls.
Developments for diseases included in the NIP The switch to the 10-valent pneumococcal vaccine (PCV10) in 2011 reduced the number of invasive pneumococcal diseases caused by the additional PCV10 serotypes in the vaccinated age groups. A decrease in the incidence of IPD caused by the additional PCV10 serotypes was also seen in the adult age groups, which is probably due to indirect protection. The incidence of pertussis increased in 2014 after a lower incidence in 2013, but was somewhat lower than during the epidemic year 2012. The incidence of mumps was low in 2014, but a resurgence of mumps and an endemic transmission were encountered in the first few months of 2015. The majority of the measles cases reported in 2014 belonged to the measles epidemic in the Bible Belt, which started in 2013. No cases of polio were reported. The environmental routine surveillance, which was intensified in the region where refugees were first cared for in 2013, was changed to routine level again in April 2015.
Developments for future NIP candidates The Health Council could advise the Dutch Minister of Health, Welfare and Sports on expansion of the NIP. The National Institute for Public Health and the Environment in the Netherlands (RIVM) investigates developments in potential future NIP candidates. In 2014, the rotavirus season was exceptionally low. A decrease in meningococcal serogroup B disease was seen in 2014. Incidences of varicella zoster virus and hepatitis A remained stable over the previous years.